Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?

被引：1
|
作者：
Hohenberger, Peter [1 ]
机构：
[1] Heidelberg Univ, Fac Med, Dept Surg, Div Surg Oncol & Thorac Surg, D-68167 Mannheim, Germany
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2008年 / 5卷 / 05期
关键词：
D O I：
10.1038/ncponc1091
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：240 / 241
页数：2
相关论文
共 50 条
  • [31] Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
    Quek, Richard
    George, Suzanne
    BIOLOGICS-TARGETS & THERAPY, 2010, 4 : 19 - 31
  • [32] Imatinib: Cost-effective in the treatment of gastrointestinal stromal tumors
    Finketstein, Stan N.
    Huse, Daniel M.
    Glendenning, G. A.
    Blanke, Charles D.
    Joensuu, Heikki
    von Mehren, Margaret
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2004, 15 : 201 - 201
  • [33] International classifications of gastrointestinal stromal tumor: a clue for adjuvant imatinib treatment
    Tzen Chin-Yuan
    9TH INTERNATIONAL GASTRIC CANCER CONGRESS (IGCC 2011): A GATE TO THE FUTURE OF GASTRIC CANCER TREATMENT, 2011, : 85 - 90
  • [34] Imatinib As Adjuvant Therapy for Gastrointestinal Stromal Tumour
    Sanford, Mark
    Scott, Lesley J.
    DRUGS, 2010, 70 (15) : 1963 - 1972
  • [35] Cost-effectiveness of three years of adjuvant imatinib in gastrointestinal stromal tumors (GIST).
    Sanon, Myrlene
    Parthan, Anju
    Taylor, Douglas
    Coombs, John
    Paolantonio, Marc
    Sasane, Medha
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [36] Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors
    Fulgenzi, Claudia Angela Maria
    Napolitano, Andrea
    Faiella, Eliodoro
    Messina, Laura
    Castiello, Gennaro
    Paternostro, Flavia
    Silletta, Marianna
    Pantano, Francesco
    Tonini, Giuseppe
    Santini, Daniele
    Vincenzi, Bruno
    JOURNAL OF BONE ONCOLOGY, 2022, 34
  • [37] Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients
    Tatsuo Kanda
    Toshirou Nishida
    Norihito Wada
    Osamu Kobayashi
    Masakazu Yamamoto
    Akira Sawaki
    Narikazu Boku
    Masato Koseki
    Toshihiko Doi
    Yasushi Toh
    Yoshihiro Kakeji
    Toshiro Sugiyama
    Yoshito Komatsu
    Shojiro Kikuchi
    Kyoji Ogoshi
    Hitoshi Katai
    Kazuhito Miyachi
    Seiichi Hirota
    Atsushi Ohtsu
    International Journal of Clinical Oncology, 2013, 18 : 38 - 45
  • [38] Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients
    Kanda, Tatsuo
    Nishida, Toshirou
    Wada, Norihito
    Kobayashi, Osamu
    Yamamoto, Masakazu
    Sawaki, Akira
    Boku, Narikazu
    Koseki, Masato
    Doi, Toshihiko
    Toh, Yasushi
    Kakeji, Yoshihiro
    Sugiyama, Toshiro
    Komatsu, Yoshito
    Kikuchi, Shojiro
    Ogoshi, Kyoji
    Katai, Hitoshi
    Miyachi, Kazuhito
    Hirota, Seiichi
    Ohtsu, Atsushi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (01) : 38 - 45
  • [39] Surgical Treatment of Gastrointestinal Stromal Tumors Located in the Stomach in the Imatinib Era
    Stiekema, Jurrien
    Kol, Sabrine
    Cats, Annemieke
    Yazdi, Amir T.
    van Coevorden, Frits
    van Sandick, Johanna W.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (05): : 502 - 507
  • [40] A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment
    Yin, Yuan
    Xiang, Jin
    Tang, Sumin
    Chen, Jiaju
    Yu, Qin
    Zhang, Bo
    MEDICINE, 2016, 95 (49) : e5488
12345